Arcutis Biotherapeutics (NASDAQ:ARQT) Stock: Insider Masaru Matsuda Sells 1,219 Shares

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) EVP Masaru Matsuda sold 1,219 shares of Arcutis Biotherapeutics stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $31.86, for a total transaction of $38,837.34. Following the completion of the sale, the executive vice president directly owned 111,289 shares in the company, valued at $3,545,667.54. This represents a 1.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Masaru Matsuda also recently made the following trade(s):

• On Wednesday, November 4th, Masaru Matsuda sold 40,000 shares of Arcutis Biotherapeutics stock. The stock was sold at an average price of $34.32, for a total transaction of $1,372,800.00.
• On Wednesday, September 16th, Masaru Matsuda sold 3,674 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $91,850.00.
• On Tuesday, September 8th, Masaru Matsuda sold 9,989 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $25.03, for a total transaction of $250,024.67.

Arcutis Biotherapeutics Stock Down 20.7%

Shares of NASDAQ ARQT opened at $27.00 on Friday. The company’s 50-day simple moving average is $27.15 and its 200-day simple moving average is $25.37. Arcutis Biotherapeutics, Inc. has a 52-week low of $19.30 and a 52-week high of $34.80. The firm has a market cap of $3.39 billion, a price-to-earnings ratio of 128.58 and a beta of 1.66. The company has a quick ratio of 2.67, a current ratio of 2.92 and a debt-to-equity ratio of 0.46.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.12). Arcutis Biotherapeutics had a return on equity of 14.96% and a net margin of 5.88%. The company had revenue of $143.92 million for the quarter, compared to analyst estimates of $142.59 million. Equities analysts predict that Arcutis Biotherapeutics, Inc. will post 0.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several large investors have recently modified their holdings of the business. Pinnacle Wealth Planning Services Inc. acquired a new stake in shares of Arcutis Biotherapeutics during the third quarter worth $36,000. Nykredit A S acquired a new position in Arcutis Biotherapeutics in the second quarter valued at $63,000. Integrated Wealth Concepts LLC acquired a new position in Arcutis Biotherapeutics in the second quarter valued at $84,000. Sterling Capital Management LLC lifted its position in Arcutis Biotherapeutics by 839.3% during the third quarter. Sterling Capital Management LLC now owns 3,776 shares of the company’s stock worth $100,000 after buying an additional 3,374 shares during the period. Finally, KBC Group NV lifted its position in Arcutis Biotherapeutics by 43.2% during the first quarter. KBC Group NV now owns 4,376 shares of the company’s stock worth $103,000 after buying an additional 1,321 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ARQT. Wall Street Zen lowered Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 10th. Needham & Company LLC set a $40.00 price objective on Arcutis Biotherapeutics in a research note on Thursday. Guggenheim raised their price objective on Arcutis Biotherapeutics from $38.00 to $44.00 and gave the company a “buy” rating in a report on Monday, October 19th. Cantor Fitzgerald initiated coverage on shares of Arcutis Biotherapeutics in a research note on Thursday, October 15th. They set an “overweight” rating and a $48.00 target price on the stock. Finally, Morgan Stanley lifted their target price on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Arcutis Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $39.75.

Arcutis Biotherapeutics News Summary

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis began enrolling participants in a Phase 3 trial of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the treatment’s use and address a broader patient population, though the study is an early-stage catalyst rather than near-term revenue. Phase 3 study announcement
• Positive Sentiment: Third-quarter revenue was $143.92 million, modestly ahead of the approximately $142.6 million analyst consensus, providing a partial offset to the earnings miss. Quarterly earnings report
• Neutral Sentiment: Rob Lisicki was appointed chief commercial officer, effective November 4. The leadership change may support commercial execution, but its impact on sales remains to be seen. Chief commercial officer appointment
• Neutral Sentiment: Several executives reported share sales, including a larger sale by EVP Masaru Matsuda under a pre-arranged trading plan. Some reported transactions were to cover tax withholding on vested equity awards, which makes them less clearly bearish, though insider selling may attract investor attention. SEC insider filing
• Negative Sentiment: Third-quarter earnings were $0.06 per share, well below analysts’ estimates of roughly $0.17–$0.18 and unchanged from a year earlier. The earnings miss was the clearest near-term pressure on the stock, despite the modest revenue beat. Report on the earnings miss

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.